Alexion Sets Up Shop in Ireland
Alexion Pharmaceuticals to Establish Global Supply Chain and Quality Operations in Ireland
New Dublin Facility Will Serve Patients with Life-Threatening Ultra-Rare Disorders in 50 Countries
Dublin, 26 July 2013: The Minister for Jobs, Enterprise and Innovation Richard Bruton, TD today announced that Alexion Pharmaceuticals is expanding its global presence with the opening of a new office and laboratory facility in Dublin in conjunction with the company’s decision to establish a global supply chain facility in Ireland. Alexion has begun the process of recruiting approximately 50 employees by year-end for a range of initial positions in its supply chain, quality assurance, quality control and logistics functions by year-end.
Alexion’s new, additional global supply chain and quality staff in Ireland are expected to begin supplying Soliris® (eculizumab) to patients with PNH and aHUS, two severe and life-threatening ultra-rare disorders, by the end of 2013. The company’s expanding Irish workforce will also manage the supply of additional Alexion medicines to patients following regulatory approvals for a series of anticipated launches of new therapies over the next several years. Today’s announcement is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
“Ireland’s government and universities have an unparalleled commitment and robust partnerships with regard to education and training for pharmaceutical manufacturing, quality assurance, quality control and supply logistics. For these reasons, as we continue to expand our global supply chain and quality team, we are very pleased to come to Ireland for its highly skilled and educated workforce,” said Stephen Squinto, PhD, Executive Vice President and Chief Global Operations Officer at Alexion. “We look forward to the role that our new colleagues in Ireland will play in helping us to provide life-transforming medicines like Soliris to more patients in more countries worldwide”.
Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on the development and delivery of therapies for severe and life-threatening diseases that are also ultra-rare. The addition of employees in Ireland is part of the on-going expansion in the company’s global organisation.
Minister Bruton said: “Sustaining and building on our strong track record in pharmaceuticals is a key objective of our Action Plan for Jobs, and the past two years we have seen some major jobs wins in this sector. Today’s announcement that Alexion is establishing a new operation in Dublin with the creation of 50 jobs is another significant jobs boost for the sector, and I wish all involved every success with their operations here. I am determined that, through continued strong implementation of our plan, we can see further jobs wins in this sector to help create the jobs we need”.
Barry O’Leary, CEO of IDA Ireland "BioPharma companies like Alexion are currently developing the “next generation” of medicines. BioPharma differs from more traditional pharmaceutical methods in that it derives the final product from living organisms. This activity represents the cutting edge of innovative drug development and requires skilled, highly qualified staff."
IDA Ireland has set out to attract the leading players in the BioPharma field to base themselves here in Ireland. With Alexion announcing their entry into Ireland, IDA Ireland has now secured seven of the top ten global BioPharma companies.
For further information on jobs in Ireland at Alexion Pharmaceutical, log onto www.cpl.ie.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. The treatment is currently approved in nearly 50 countries for the treatment of PNH, and in the United States, Canada and the European Union for the treatment of aHUS. Alexion is evaluating other potential indications for its marketed drug and is developing four other highly innovative biotechnology product candidates, which are being investigated across nine severe and ultra-rare disorders beyond PNH and aHUS. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com.
For further information:
Irving Adler, Executive Director, Corporate Communications. Tel: +1-203-271-8210
Kevin Sammon, Head of Public Relations, Mob: +353 (0) 87 6188564
Posted: July 2013